ARCA biopharma, Inc. (ABIO)
Total Valuation
ARCA biopharma has a market cap or net worth of $24.50 million. The enterprise value is -$13.77 million.
| Market Cap | 24.50M |
| Enterprise Value | -13.77M |
Important Dates
The next estimated earnings date is Friday, February 23, 2024, after market close.
| Earnings Date | Feb 23, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ARCA biopharma has 14.41 million shares outstanding.
| Shares Outstanding | 14.41M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 1.30% |
| Owned by Institutions (%) | 50.62% |
| Float | 9.12M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.65 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 39.21, with a Debt / Equity ratio of 0.01.
| Current Ratio | 39.21 |
| Quick Ratio | n/a |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -13.60% and return on invested capital (ROIC) is -18.99%.
| Return on Equity (ROE) | -13.60% |
| Return on Assets (ROA) | -13.10% |
| Return on Capital (ROIC) | -18.99% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.08M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -30.04% in the last 52 weeks. The beta is 1.39, so ARCA biopharma's price volatility has been higher than the market average.
| Beta (1Y) | 1.39 |
| 52-Week Price Change | -30.04% |
| 50-Day Moving Average | 1.83 |
| 200-Day Moving Average | 1.99 |
| Relative Strength Index (RSI) | 32.13 |
| Average Volume (30 Days) | 23,222 |
Short Selling Information
The latest short interest is 212,232, so 1.47% of the outstanding shares have been sold short.
| Short Interest | 212,232 |
| Short Previous Month | 204,338 |
| Short % of Shares Out | 1.47% |
| Short % of Float | 2.33% |
| Short Ratio (days to cover) | 12.22 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -7.25M |
| Pretax Income | -5.42M |
| Net Income | -5.42M |
| EBITDA | -5.31M |
| EBIT | -5.42M |
| Earnings Per Share (EPS) | -$0.37 |
Balance Sheet
The company has $38.49 million in cash and $224,000 in debt, giving a net cash position of $38.26 million or $2.66 per share.
| Cash & Cash Equivalents | 38.49M |
| Total Debt | 224,000 |
| Net Cash | 38.26M |
| Net Cash Per Share | $2.66 |
| Equity / Book Value | 37.97M |
| Book Value Per Share | 2.63 |
| Working Capital | 37.90M |
Cash Flow
| Operating Cash Flow | -5.45M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.45M |
| FCF Per Share | -$0.38 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ARCA biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -22.14% |
| FCF Yield | -22.26% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on April 4, 2019. It was a reverse split with a ratio of 1:18.
| Last Split Date | Apr 4, 2019 |
| Split Type | Reverse |
| Split Ratio | 1:18 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |